{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:26:25Z","timestamp":1785551185693,"version":"3.56.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Partly due to its clinical heterogeneity, hidradenitis suppurativa (HS) is difficult to score accurately; illustrated by the large number of disease scores. In 2016, a systematic review by Ingram et al. reported the use of about thirty scores, and since then, this number has increased further. Our aim is twofold: to provide a succinct but detailed narrative review of the scores used to date, and to compare these scores with each other for individual patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The review of the literature was done among articles in English and French, on Google, Google scholar, Pubmed, ScienceDirect and Cochrane. To illustrate the differences between scores, data from some Belgian patients included in the European Registry for HS were selected. A first series of patients compares the severity of the following scores: Hurley, Hurley Staging refined, three versions of Sartorius score (2003, 2007, 2009), Hidradenitis Suppurativa Physician Global Assessment (HS-PGA), International Hidradenitis Suppurativa Severity Scoring System (IHS4), Severity Assessment of Hidradenitis Suppurativa (SAHS), Hidradenitis Suppurativa Severity Index (HSSI), Acne Inversa Severity Index (AISI), the Static Metascore, and one score that is not specific to HS: Dermatology Life Quality Index (DLQI). A second set of patients illustrates how some scores change over time and with treatment: Hurley, Hurley Staging refined, Sartorius 2003, Sartorius 2007, HS-PGA, IHS4, SAHS, AISI, Hidradenitis Suppurativa Clinical Response (HiSCR), the very new iHS4-55, the Dynamic Metascore, and DLQI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen scores are detailed in this overview. We illustrate that for some patients, the scores do not predictably and consistently correlate with each other, either in an evaluation of the severity at a time-point t, or in the evaluation of the response to a treatment. Some patients in this cohort may be considered responders according to some scores, but non-responders according to others. The clinical heterogeneity of the disease, represented by its many phenotypes, seems partly to explain this difference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These examples illustrate how the choice of a score can lead to different interpretations of the response to a treatment, or even potentially change the results of a randomized clinical trial.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1145152","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T05:30:51Z","timestamp":1681709451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data"],"prefix":"10.3389","volume":"10","author":[{"given":"Mathieu","family":"Daoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Suppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Benhadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Daxhelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane","family":"Njimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","article-title":"Comorbidities of hidradenitis suppurativa (acne inversa).","volume":"2","author":"Fimmel","year":"2010","journal-title":"Dermatoendocrinol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-33101-8_2","article-title":"Verneuil and Verneuil\u2019s Disease: an Historical Overview.","author":"Tilles","year":"2006","journal-title":"Hidradenitis Suppurativa."},{"key":"B3","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach.","author":"Hurley","year":"1989","journal-title":"Dermatologic surgery: principles and practice."},{"key":"B4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000507348","article-title":"Proposed definitions of typical lesions in hidradenitis suppurativa.","volume":"236","author":"Daxhelet","year":"2020","journal-title":"Dermatology."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18707","article-title":"Scoring hidradenitis suppurativa: How to simplify data collection?","author":"Daoud","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/jdv.13267","article-title":"Establishment of a European Registry for hidradenitis suppurativa\/acne inversa by using an open source software.","volume":"30","author":"Daxhelet","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1111\/jdv.17023","article-title":"European registry for hidradenitis suppurativa: state of play.","volume":"35","author":"Daxhelet","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000501771","article-title":"Could residents adequately assess the severity of hidradenitis suppurativa? Interrater and intrarater reliability assessment of major scoring systems.","volume":"236","author":"W\u0142odarek","year":"2019","journal-title":"Dermatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1111\/ijd.15295","article-title":"A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa.","volume":"60","author":"Shaver","year":"2020","journal-title":"Int J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bjd.17769","article-title":"Refining the hidradenitis suppurativa Hurley staging system for mild, moderate and severe disease.","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment.","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.annder.2015.07.012","article-title":"\u00c9valuation clinique de la s\u00e9v\u00e9rit\u00e9 de l\u2019hidrad\u00e9nite suppur\u00e9e \u2013 maladie de Verneuil.","volume":"142","author":"Revuz","year":"2015","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the dutch hidradenitis suppurativa expert group.","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.18158","article-title":"Severity staging of hidradenitis suppurativa: Is Hurley classification the answer?","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa.","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0151-9638(07)91613-0","article-title":"Modifications et mode d\u2019emploi du score de Sartorius pour \u00e9valuer la gravit\u00e9 de l\u2019hidrad\u00e9nite suppur\u00e9e.","volume":"134","author":"Revuz","year":"2007","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ced.12459","article-title":"New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study.","volume":"40","author":"Fadel","year":"2015","journal-title":"Clin Exp Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1524-4725.2009.01214.x","article-title":"Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser.","volume":"35","author":"Tierney","year":"2009","journal-title":"Dermatol Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/PRS.0b013e31821e6fb5","article-title":"Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study.","volume":"128","author":"Highton","year":"2011","journal-title":"Plast Reconstr Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","article-title":"A novel severity assessment scoring system for hidradenitis suppurativa.","volume":"154","author":"Hessam","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","article-title":"A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.","volume":"49","author":"Amano","year":"2010","journal-title":"Int J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018.","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bjd.13396","article-title":"Hidradenitis suppurativa outcome measures and treatment goals.","volume":"171","author":"Ingram","year":"2014","journal-title":"Br J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/exd.14609","article-title":"New treatments and new assessment instruments for Hidradenitis suppurativa.","author":"van Straalen","year":"2022","journal-title":"Exp Dermatol."},{"key":"B32","first-page":"258","article-title":"AISI: a new disease severity assessment tool for hidradenitis suppurativa.","volume":"27","author":"Chiricozzi","year":"2015","journal-title":"Wounds."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined hurley classification for hidradenitis suppurativa with patient reported quality of life and objective disease severity assessment.","volume":"180","author":"Rondags","year":"2018","journal-title":"Br J Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.","volume":"37","author":"Tzellos","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.","volume":"85","author":"van Straalen","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1599","article-title":"Distinguishing mild, moderate, and severe hidradenitis suppurativa.","volume":"154","author":"Kokolakis","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1111\/jdv.16704","article-title":"What counts? The relationship between patient estimated numbers of painful hidradenitis suppurativa lesions over 4 weeks compared with clinician\u2019s lesion count at the time of examination.","volume":"34","author":"Kjaersgaard Andersen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjd.19565","article-title":"Hidradenitis suppurativa area and severity index revised (HASI-R): psychometric property assessment.","volume":"184","author":"Goldfarb","year":"2020","journal-title":"Br J Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjd.18244","article-title":"Severity and area score for hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.","volume":"182","author":"Kirby","year":"2019","journal-title":"Br J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjd.18335","article-title":"Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa.","volume":"182","author":"Goldfarb","year":"2019","journal-title":"Br J Dermatol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014733","article-title":"Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.","volume":"7","author":"Thorlacius","year":"2017","journal-title":"BMJ Open."},{"key":"B43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international delphi process.","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bjd.16093","article-title":"Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.","volume":"178","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/jdv.16328","article-title":"Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore.","volume":"34","author":"Marzano","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1111\/jdv.15122","article-title":"HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa.","volume":"33","author":"Chiricozzi","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000488344","article-title":"A retrospective cohort study on patients with Hidradenitis Suppurativa.","volume":"234","author":"Seyed Jafari","year":"2018","journal-title":"Dermatology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1111\/jdv.17022","article-title":"Metascoring Hidradenitis suppurativa.","volume":"35","author":"Daoud","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjd.21236","article-title":"Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.","volume":"187","author":"Garg","year":"2022","journal-title":"Br J Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection.","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00105-017-4082-5","article-title":"Acne inversa\/hidradenitis suppurativa: an update.","volume":"68","author":"Sabat","year":"2017","journal-title":"Hautarzt."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/dsu.12329","article-title":"Ultrasound in-depth characterization and staging of Hidradenitis suppurativa.","volume":"39","author":"Wortsman","year":"2013","journal-title":"Dermatol Surgery."},{"key":"B54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.23736\/S2784-8671.18.06196-5","article-title":"Comparison of clinical and sonographic scores in hidradenitis suppurativa and proposal of a novel ultrasound scoring system.","volume":"156","author":"Nazzaro","year":"2018","journal-title":"Ital Dermatol Venereol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5114\/ada.2021.104274","article-title":"Medical infrared thermography as hidradenitis suppurativa diagnostic tool: literature review.","volume":"38","author":"Mazeika","year":"2021","journal-title":"Postepy Dermatol Alergol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/srt.12750","article-title":"Infrared thermography and color Doppler: two combined tools for assessing inflammation in hidradenitis suppurativa.","volume":"26","author":"Nazzaro","year":"2019","journal-title":"Skin Res Technol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3647","article-title":"Correlation between depression, quality of life and clinical severity in patients with Hidradenitis Suppurativa.","volume":"100","author":"Sampogna","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/jdv.15519","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.","volume":"183","author":"Kirby","year":"2019","journal-title":"Br J Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000518965","article-title":"Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large dutch cohort.","volume":"238","author":"Dudink","year":"2021","journal-title":"Dermatology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bjd.14418","article-title":"Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality.","volume":"174","author":"Ingram","year":"2016","journal-title":"Br J Dermatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.18035","article-title":"A narrative review of the definition of \u00ab flare \u00bb in hidradenitis suppurativa.","volume":"182","author":"Kirby","year":"2020","journal-title":"Br J Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jdin.2020.09.005","article-title":"Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: implications for outcome measures and trial design.","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa.","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B66","year":"2022","journal-title":"01-2022-InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1145152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T05:30:54Z","timestamp":1681709454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1145152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":66,"alternative-id":["10.3389\/fmed.2023.1145152"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1145152","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1145152"}}